IP Library Granted Patent US 10,041,127
Granted Patent B2
US 10,041,127 · App. 14/425,189 · Granted Aug 7, 2018

Systems and methods to detect rare mutations and copy number variation

Inventor: AmirAli Talasaz (Menlo Park, CA)
Assignee: Guardant Health, Inc.
C12Q1/6886C12N15/1065C12Q1/6806C12Q1/6869C12Q1/6874G06F19/22C12Q2600/118C12Q2600/156C12Q2600/158C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,041,127
App. No.
14/425,189
Granted
Aug 7, 2018
Kind
B2
Abstract

The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.

Claims (28)

1. A method, comprising:

a) non-uniquely tagging a population of extracellular polynucleotides obtained from a bodily sample from a subject to produce a population of non-uniquely tagged extracellular polynucleotides;

b) sequencing the population of non-uniquely tagged extracellular polynucleotides to produce a base call at a mappable position in the non-uniquely tagged extracellular polynucleotides; and

c) for the base call at the mappable position, measuring a frequency of unique molecules containing the base call in relation to the total number of unique molecules having a base call;

wherein a frequency of unique molecules containing the base call at the mappable position that is above a set measure of deviation from a plurality of reference sequences indicates a rare mutation at the mappable position.

2. The method of claim 1 , further comprising isolating extracellular polynucleotides from the bodily sample.

3. The method of claim 1 , further comprising amplifying the population of non-uniquely tagged extracellular polynucleotides prior to sequencing.

4. The method of claim 1 , wherein non-uniquely tagging comprises attaching one or more barcodes to the population of extracellular polynucleotides prior to sequencing.

5. The method of claim 4 , wherein a given barcode from the one or more barcodes comprises a fixed or semi-random oligonucleotide sequence that in combination with a diversity of molecules sequenced from a select region enables identification of unique molecules.

6. The method of claim 1 , further comprising selectively enriching regions from a genome or transcriptome of the subject from the population of non-uniquely tagged extracellular polynucleotides prior to sequencing.

7. The method of claim 3 , wherein the population of extracellular polynucleotides is non-uniquely tagged prior to amplifying.

8. The method of claim 1 , wherein producing the base call comprises voting, averaging, maximum a posteriori or maximum likelihood detection, dynamic programming, Bayesian methods, hidden Markov methods, or support vector machine methods.

9. The method of claim 1 , wherein sequencing comprises obtaining sequencing reads, which sequencing reads are used to generate a set of consensus sequences, wherein measuring the frequency comprises detecting a presence of a sequence variation in the set of consensus sequences compared with the plurality of reference sequences.

10. The method of claim 1 , further comprising detecting a presence of sequence variations for a panel of oncogenes.

11. The method of claim 1 , wherein sequencing comprises obtaining sequencing reads, which sequencing reads are mapped, wherein mapping the sequence reads comprises using information about a length of each of the sequence reads.

12. The method of claim 1 , wherein the population of extracellular polynucleotides is tagged with from 10 to 100,000 different identifiers.

13. The method of claim 1 , wherein the population of extracellular polynucleotides is tagged with n different unique identifiers, wherein n is no more than 100*z, wherein z is a mean of an expected number of duplicate molecules having the same start and stop positions in the bodily sample.

14. The method of claim 1 , wherein the population of extracellular polynucleotides obtained from the bodily sample comprises no more than 100 nanograms of extracellular polynucleotides.

15. The method of claim 1 , further comprising converting the population of extracellular polynucleotides into a population of non-uniquely tagged parent polynucleotides at a conversion efficiency of at least 30%.

16. The method of claim 1 , further comprising converting the population of extracellular polynucleotides into a population of non-uniquely tagged parent polynucleotides at a conversion efficiency of at least 50%.

17. The method of claim 1 , further comprising converting the population of extracellular polynucleotides into a population of non-uniquely tagged parent polynucleotides at a conversion efficiency of at least 80%.

18. The method of claim 1 , further comprising selectively enriching regions from a genome or transcriptome from the population of extracellular polynucleotides prior to sequencing.

19. The method of claim 1 , wherein sequencing comprises obtaining sequencing reads.

20. The method of claim 19 , further comprising grouping the sequencing reads into families.

21. The method of claim 20 , wherein a given family comprises duplicate sequencing reads.

22. The method of claim 21 , wherein a given family comprises sequencing reads with the same start and stop positions and barcodes.

23. The method of claim 1 , wherein the measure of deviation is a measure of variance.

24. The method of claim 1 , wherein the population of extracellular polynucleotides is tagged with from 50 to 10,000 different identifiers.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2015
From: TALASAZ, AMIRALI; ELTOUKHY, HELMY
To: GUARDANT HEALTH, INC.
Reel/Frame 035180/0568 →
Continuity (5)
Provisional Application 61696734 · Sep 4, 2012
Provisional Application 61704400 · Sep 21, 2012
Provisional Application 61793997 · Mar 15, 2013
Provisional Application 61845987 · Jul 13, 2013
Related Publication 20150368708A1 · Dec 24, 2015
Cited By (34)
US 12,195,803 US 12,203,142 US 12,209,281 US 12,221,653 US 12,234,509 US 12,252,743 US 12,260,934 US 12,270,073 US 12,305,229 US 12,305,235 US 12,385,096 US 12,410,476 US 12,442,038 US 12,460,264 US 12,473,589 US 12,486,542 US 12,492,429 US 12,492,434 US 12,509,728 US 12,534,759 US 12,553,082 US 12,553,083 US 12,553,086 US 12,571,034 US 12,571,043 US 12,571,047 US 12,584,163 US 12,644,149 US 12,649,946 US 12,655,483 US 12,662,704 US 12,668,893 US 12,674,158 US 12,716,090